Pathway identified for overcoming treatment resistance in a particular type of leukemia

A study led Dr. Anna Bigas, Principal Investigator of the Stem Cell and Cancer Research Group at Josep Carreras Leukaemia Research Institute and Hospital del Mar Medical Research Institute, has revealed the key role a protein plays in identifying patients with T-cell acute lymphoblastic leukemia who will not respond to standard treatment.

The study, published in the journal EMBO Molecular Medicine, shows that combining chemotherapy with an inhibitor for this protein helps to eliminate treatment resistance in an animal model.

This is a rare disease, which is diagnosed in around a hundred people each year in Spain, mainly pediatric patients.

Webpage updated 12/01/2023 13:27:05